News
- Author:
- Andrew D. Bowser
Publish date: November 6, 2019
Investigators reported that the regimen’s efficacy is on par with R-hyperCVAD, but is less toxic.
News
- Author:
- Andrew D. Bowser
Publish date: November 5, 2019
Longer-term data suggest a maintenance of effect in patients who continued on an open-label extension.
News
- Author:
- Andrew D. Bowser
Publish date: October 27, 2019
Emicizumab stands to become the “next-generation standard of care” for these pediatric patients, report says.
News
- Author:
- Andrew D. Bowser
Publish date: October 26, 2019
PHILADELPHIA – No-show rates cut by about one-third for patients who met their clinician via video.
News
- Author:
- Andrew D. Bowser
Publish date: October 26, 2019
NEW ORLEANS – Results suggest need for ongoing patient education beyond the initial shared decision-making encounter.
News
- Author:
- Andrew D. Bowser
Publish date: October 25, 2019
NEW ORLEANS – Reduction of readmission rates has potential to improve health and economic outcomes, according to researchers.
News
- Author:
- Andrew D. Bowser
Publish date: October 23, 2019
NEW ORLEANS – The test is seen as complementary to bronchoscopy, improving the sensitivity of bronchoscopy.
News
- Author:
- Andrew D. Bowser
Publish date: October 22, 2019
NEW ORLEANS – Results from the randomized, phase 3 VICTAS study, anticipated in the coming months, may shed light on ...
News
- Author:
- Andrew D. Bowser
Publish date: October 22, 2019
NEW ORLEANS – A history of recent exacerbations didn’t significantly affect the safety or efficacy of aclidinium bromide in patients with moderate ...
News
- Author:
- Andrew D. Bowser
Publish date: October 22, 2019
NEW ORLEANS – In-hospital influenza vaccination linked to lower readmission rates in database analysis.
News
- Author:
- Andrew D. Bowser
Publish date: October 21, 2019
NEW ORLEANS – More discharges to hospice, and more health care surrogates chosen, when palliative care consultation occurs within 24 hours of ICU a...
News
- Author:
- Andrew D. Bowser
Publish date: October 21, 2019
NEW ORLEANS – If it’s an option, clinicians should consider donor-to-recipient race compatibility.
News
- Author:
- Andrew D. Bowser
Publish date: October 21, 2019
PHILADELPHIA – After 12 weeks, 86% of the patiromer patients remained on spironolactone, vs. 66% of the placebo patients.
News
- Author:
- Andrew D. Bowser
Publish date: October 21, 2019
NEW ORLEANS – Length of stay, number of ventilator days both reduced with use of the standardized instrument.
News
- Author:
- Andrew D. Bowser
Publish date: October 17, 2019
Both lupus low disease activity state and complete remission by 6 months translated into less damage at 18 months in retrospective analysis.
